ArticlePharmaceutics2022
Colistin Interaction and Surface Changes Associated with
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Activity of Lysozyme Against Multidrug-ResistantAnimals : an open access journal from MDPI · 2025Article
- Metabolism-dependent succinylation governs resource allocation for antibiotic resistance.Science advances · 2025Article
- Mechanisms of Polymyxin Resistance in Acid-Adapted EnteroinvasiveMicroorganisms · 2024Article
- Synergistic effects of oxidative and acid stress on bacterial membranes of Escherichia coli and Staphylococcus simulans.Communications biology · 2024Article
- The Controversial Effect of Antibiotics on Methicillin-SensitiveInternational journal of molecular sciences · 2023Article
- Untying the anchor for the lipopolysaccharide: lipid A structural modification systems offer diagnostic and therapeutic options to tackle polymyxin resistance.Arhiv za higijenu rada i toksikologiju · 2023Review
- Chemically Enhanced Peptide and Protein Therapeutics.Pharmaceutics · 2023Article
- Molecular Genetic Epidemiology of an Emerging Antimicrobial-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Synergistic Activity of Tetrandrine and Colistin againstAntibiotics (Basel, Switzerland) · 2022Article
- Review
- Article
- The Sources and Potential Hosts Identification of Antibiotic Resistance Genes in the Yellow River, Revealed by Metagenomic Analysis.International journal of environmental research and public health · 2022Article
- Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Inactivation ofFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colistin, a polycationic antimicrobial peptide, is one of the last-resort antibiotics for treating infections caused by carbapenem-resistant Gram-negative bacteria. The antibacterial activity of colistin occurs through electrostatic interaction between the polycationic peptide group of colistin and the negatively charged phosphate groups of lipid A membrane. This study investigated the interaction of colistin with the outer membrane and surface constituents of resistant and susceptible strains of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.